Results 31 to 40 of about 18,680 (231)

Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy

, 2021
Indoleamine 2,3-dioxygenase-1 (IDO1) plays an important role in tumor immune escape. However, unsatisfactory clinical efficacies of selective IDO1 inhibitors have impeded their further development, suggesting that they do not exert sufficient antitumor ...
Zhaoxing Chu (7536365), Jinxi Shan (11784280), Hui Shen (66625), Shan Zhang (431282), Yi Zou (439002), Yiran Ge (8194932), Zhifeng Wei (11453658), Huanhuan Wu (339728), Junjie Wang (172690), Kewen Peng (8194929), Xin He (48101), Qihua Zhu (1555147), Guangchao He (8194926), Yungen Xu (1434802)   +13 more
core   +3 more sources

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

Journal of Hematology & Oncology, 2021
Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme enzyme that catalyzes the oxidation of L-tryptophan. Functionally, IDO1 has played a pivotal role in cancer immune escape via catalyzing the initial step of the kynurenine pathway, and overexpression of IDO1
Kai Tang, Ya-Hong Wu, Yihui Song, Bin Yu
doaj   +1 more source

Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation

Clinical and Developmental Immunology, 2012
The role of the tryptophan-catabolizing enzyme, indoleamine 2,3-dioxygenase (IDO1), in tumor escape and metastasis formation was analyzed using two pairs of Ido1+ and Ido1− murine breast cancer cell lines. Ido1 expression in 4T1 cells was knocked down by
Vera Levina, Yunyun Su, Elieser Gorelik
doaj   +1 more source

miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer

Journal for ImmunoTherapy of Cancer, 2019
Background Indoleamine 2,3-dioxygenase 1 (IDO1) is a critical regulator of T cell function, contributing to immune tolerance. Upregulation of IDO1 has been found in many cancer types; however, the regulatory mechanisms and clinical significance of IDO1 ...
Qiong Lou, Ruixian Liu, Xiangling Yang, Weiqian Li, Lanlan Huang, Lili Wei, Huiliu Tan, Nanlin Xiang, Kawo Chan, Junxiong Chen, Huanliang Liu   +10 more
doaj   +1 more source

Synthesis and activity study of novel N,N-diphenylurea derivatives as IDO1 inhibitors

Frontiers in Chemistry, 2023
Indoleamine 2,3-dioxygenase 1 (IDO1) has attracted much attention in the field of cancer immunotherapy as an immunomodulatory enzyme. To identify potential IDO1 inhibitors, a novel series of compounds with N,N-diphenylurea and triazole structures were ...
Xi-Xi Hou, Zi-Yuan Wu, Zi-Yuan Wu, An Zhan, An Zhan, En Gao, En Gao, Long-Fei Mao, Hui-Li Wang, Jian-Xue Yang, Jian-Xue Yang   +10 more
doaj   +1 more source

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

OncoImmunology, 2020
CD40-stimulating immunotherapy can elicit potent anti-tumor responses by activating dendritic cells and enhancing T-cell priming. Tumor vessels orchestrate T-cell recruitment during immune response, but the effect of CD40-stimulating immunotherapy on ...
Maria Georganaki, Mohanraj Ramachandran, Sander Tuit, Nicolás Gonzalo Núñez, Alexandros Karampatzakis, Grammatiki Fotaki, Luuk van Hooren, Hua Huang, Roberta Lugano, Thomas Ulas, Aura Kaunisto, Eric C Holland, Peter Ellmark, Sara M Mangsbo, Joachim Schultze, Magnus Essand, Sonia Tugues, Anna Dimberg   +17 more
doaj   +1 more source

Expression of IDO1 and PD-L2 in Patients with Benign Lymphadenopathies and Association with Autoimmune Diseases

Biomolecules, 2023
The expression patterns of IDO1 and PD-L2 have not been thoroughly investigated in benign lymphadenopathies. The aim with this study was to elucidate how IDO1 and PD-L2 are expressed in benign lymphadenopathies in patients with autoimmune diseases (AD ...
Maysaa Abdulla, Christer Sundström, Cecilia Lindskog, Peter Hollander   +3 more
doaj   +1 more source

Class IA PI3Ks regulate subcellular and functional dynamics of IDO1 [PDF]

, 2020
Knowledge of a protein’s spatial dynamics at the subcellular level is key to understanding its function(s), interactions, and associated intracellular events.
Gargaro M., Proietti E., Iamandii I. M., Llena Sopena J., Stark A. -K., Belladonna M. L., Milano F., Albini E., Orabona C., Hawkins P., Coletti A., Puccetti P., Martelli M. P., Suire S., Greco F. A., Iacono A., Panfili E., Volpi C., Vacca C., Pompa A., Mazza E. M. C., Mondanelli G., Okkenhaug K., Grassi F., Bicciato S., Graupera Garcia-Mila M., Fallarino F., Macchiarulo A., Pallotta M. T., Bellucci M., Bianchi R., Grohmann U., De Marchis F., Santambrogio L., De Marcos Lousa C.   +34 more
core   +3 more sources

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer

Journal for ImmunoTherapy of Cancer, 2017
Background Immunostimulatory therapies targeting immune-suppressive pathways produce durable responses in advanced solid tumors. Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting oxidoreductase that catalyzes the degradation of tryptophan to ...
Daniel E. Carvajal-Hausdorf, Nikita Mani, Vamsidhar Velcheti, Kurt A. Schalper, David L. Rimm   +4 more
doaj   +1 more source

Issues with the Specificity of Immunological Reagents for Murine IDO1 [PDF]

Cell Metabolism, 2016
In a recent report in Cell Metabolism, Metghalchi et al. presented evidence suggesting a negative regulatory link between the tryptophan-degrading enzyme IDO1 and IL-10 that was proposed to influence the outcomes of atherosclerosis and colitis (Metghalchi et al., 2015).
Van de Velde, Lee-Ann, Gingras, Sebastien, Pelletier, Stephane, Murray, Peter J.   +3 more
openaire   +2 more sources